From the Chief Executive
The only place ‘cake’ has in the Grattan Institute’s recommendation to slash medicine prices is the policy’s similarity to the ignorant princess exhorting the peasants to ‘eat cake’ in the midst of a famine.
The Pharmaceutical Benefits Scheme has served this country very well since its creation in 1948. Over the decades, it has played a central role in
But the Institute’s insistence that we can now have our (medicine) cake and eat it too – that we can arbitrarily slash prices and maintain universal access to the latest life-saving medicines – is fanciful.
News and Updates
The Medicines Australia Board announced today that it has appointed Mr Tim James as the new Chief Executive for the organisation.
Mr James will replace outgoing Chief Executive, Dr Brendan Shaw, who finished in his role on 12 September to take up a senior role with the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) in Geneva.
Medicines Australia Chairman, Dr Martin Cross, welcomed the appointment of Mr James to the position.
The decision by the Federal Court to allow patenting of genetic materials highlights the importance of maintaining strong intellectual property laws to promote the development of new medicines, the Chief Executive of Medicines Australia Dr Brendan Shaw said today.
“Patents on biological agents such as isolated genetic materials are important because they ensure ongoing investment in developing cutting-edge medicines and diagnostic tests,” Dr Shaw said.
Medicines Australia today congratulated Mr Martin Bowles on his appointment as Secretary of the Department of Health.
Chief Executive of Medicines Australia, Dr Brendan Shaw, said the industry welcomed the opportunity to work with Mr Martin Bowles as head of the Department of Health.
“We look forward to working with Mr Bowles to maintain and develop Australia’s system of providing medicines to the Australian community and improving the health of Australians,” Dr Shaw said.
The Grattan Institute’s PBS savings proposal has been proven wrong after their admission this week that the savings figure was artificially inflated by (at least) $165 million, or almost 40%.
Appearing before the Senate Community Affairs Committee this week, the Institute acknowledged that the proposed annual savings from benchmarking 20 commonly-used drugs against UK prices was not $580 million, as originally claimed, but actually closer to $415 million.